{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:06:35Z","timestamp":1790604395755,"version":"4.1.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2022,1,21]]},"abstract":"<jats:p>Background: The MDS-Unified Parkinson\u2019s disease (PD) Rating Scale (MDS-UPDRS) is the most used scale in clinical trials. Little is known about the predictive potential of its single items. Objective: To systematically dissect MDS-UPDRS to predict PD progression. Methods: 574 de novo PD patients and 305 healthy controls were investigated at baseline (BL) in the single-center DeNoPa (6-year follow-up) and multi-center PPMI (8-year follow-up) cohorts. We calculated cumulative link mixed models of single MDS-UPDRS items for odds ratios (OR) for class change within the scale. Models were adjusted for age, sex, time, and levodopa equivalent daily dose. Annual change and progression of the square roots of the MDS-UDPRS subscores and Total Score were estimated by linear mixed modeling. Results: Baseline demographics revealed more common tremor dominant subtype in DeNoPa and postural instability and gait disorders-subtype and multiethnicity in PPMI. Subscore progression estimates were higher in PPMI but showed similar slopes and progression in both cohorts. Increased ORs for faster progression were found from BL subscores I and II (activities of daily living; ADL) most marked for subscore III (rigidity of neck\/lower extremities, agility of the legs, gait, hands, and global spontaneity of movements). Tremor items showed low ORs\/negative values. Conclusion: Higher scores at baseline for ADL, freezing, and rigidity were predictors of faster deterioration in both cohorts. Precision and predictability of the MDS-UPDRS were higher in the single-center setting, indicating the need for rigorous training and\/or video documentation to improve its use in multi-center cohorts, for example, clinical trials.<\/jats:p>","DOI":"10.3233\/jpd-212860","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T12:44:31Z","timestamp":1635252271000},"page":"437-452","source":"Crossref","is-referenced-by-count":26,"title":["Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale in Two Independent Cohorts with Early Parkinson\u2019s Disease"],"prefix":"10.1177","volume":"12","author":[{"given":"Michael","family":"Bartl","sequence":"first","affiliation":[{"name":"Department of Neurology, University Medical Center Goettingen, Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Dakna","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Goettingen, Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schade","sequence":"additional","affiliation":[{"name":"Paracelsus-Elena-Klinik, Kassel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Wicke","sequence":"additional","affiliation":[{"name":"Paracelsus-Elena-Klinik, Kassel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lang","sequence":"additional","affiliation":[{"name":"Paracelsus-Elena-Klinik, Kassel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ebentheuer","sequence":"additional","affiliation":[{"name":"Paracelsus-Elena-Klinik, Kassel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrina","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Goettingen, Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[{"name":"Paracelsus-Elena-Klinik, Kassel, Germany"},{"name":"Department of Neurosurgery, University Medical Center Goettingen, Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Mollenhauer","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Goettingen, Goettingen, Germany"},{"name":"Paracelsus-Elena-Klinik, Kassel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-212860_ref1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson\u2019s Progression Markers Initiative cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-212860_ref3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2017-316213","article-title":"Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson\u2019s disease: the PPMI cohort","volume":"89","author":"Simuni","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-212860_ref4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/mds.28094","article-title":"Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale use in the Covid-19 era","volume":"35","author":"Goetz","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3233\/JPD-202121","article-title":"Remote administration of the MDS-UPDRS in the time of COVID-19 and beyond","volume":"10","author":"Schneider","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-212860_ref6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jnnp.2005.081711","article-title":"Motor subtype and cognitive decline in Parkinson\u2019s disease, Parkinson\u2019s disease with dementia, and dementia with Lewy bodies","volume":"77","author":"Burn","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-212860_ref7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1531-8257(200005)15:3<479::AID-MDS1009>3.0.CO;2-P","article-title":"Differential progression of motor impairment in levodopa-treated Parkinson\u2019s disease","volume":"15","author":"Goetz","year":"2000","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00702-016-1517-6","article-title":"MMSE and MoCA in Parkinson\u2019s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study","volume":"123","author":"Biundo","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JPD-212860_ref10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","article-title":"Biomarkers and surrogate markers: an FDA perspective","volume":"1","author":"Katz","year":"2004","journal-title":"NeuroRx"},{"key":"10.3233\/JPD-212860_ref11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2125.2012.04208.x","article-title":"Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson\u2019s disease","volume":"74","author":"Vu","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JPD-212860_ref12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.22121","article-title":"Predictors and course of health-related quality of life in Parkinson\u2019s disease","volume":"23","author":"Forsaa","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid \u03b1-Synuclein in prodromal and early Parkinson\u2019s disease","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02259659","article-title":"Effect of age and disease duration on parkinsonian motor scores under levodopa therapy","volume":"9","author":"Ransmayr","year":"1995","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.3233\/JPD-212860_ref15","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1474-4422(09)70291-1","article-title":"Progression of Parkinson\u2019s disease in the clinical phase: potential markers","volume":"8","author":"Maetzler","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-212860_ref16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2019.10.019","article-title":"Sex differences in Parkinson\u2019s disease presentation and progression","volume":"69","author":"Abraham","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212860_ref17","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1212\/WNL.0b013e3182a6cbd5","article-title":"Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort","volume":"81","author":"Mollenhauer","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JPD-212860_ref18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","article-title":"A clinicopathologic study of 100 cases of Parkinson\u2019s disease","volume":"50","author":"Hughes","year":"1993","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-212860_ref19","doi-asserted-by":"crossref","first-page":"e0175674","DOI":"10.1371\/journal.pone.0175674","article-title":"Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease","volume":"12","author":"Caspell-Garcia","year":"2017","journal-title":"PLoS One"},{"key":"10.3233\/JPD-212860_ref20","unstructured":"(2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95, 629\u2013635."},{"key":"10.3233\/JPD-212860_ref21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1212\/WNL.0000000000002651","article-title":"Monitoring of 30 marker candidates in early Parkinson disease as progression markers","volume":"87","author":"Mollenhauer","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JPD-212860_ref22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/mds.10248","article-title":"Systematic evaluation of rating scales for impairment and disability in Parkinson\u2019s disease","volume":"17","author":"Ramaker","year":"2002","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.21198","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref25","doi-asserted-by":"crossref","unstructured":"(2003) The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18, 738\u2013750.","DOI":"10.1002\/mds.10473"},{"key":"10.3233\/JPD-212860_ref26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mdc3.12476","article-title":"Differences in MDS-UPDRS scores based on Hoehn and Yahr Stage and disease duration","volume":"4","author":"Skorvanek","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-212860_ref27","doi-asserted-by":"crossref","unstructured":"(1989) DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease. Parkinson Study Group. Arch Neurol 46, 1052\u20131060.","DOI":"10.1001\/archneur.1989.00520460028009"},{"key":"10.3233\/JPD-212860_ref28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease (the ADAGIO study): prespecified and analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes","volume":"10","author":"Rascol","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-212860_ref29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.22060","article-title":"Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study","volume":"68","author":"Stocchi","year":"2010","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-212860_ref30","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide","volume":"7","author":"Schade","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-212860_ref32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1212\/WNL.0b013e3182a6cbd5","article-title":"Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort","volume":"81","author":"Mollenhauer","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JPD-212860_ref33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.22335","article-title":"UPDRS activity of daily living score as a marker of Parkinson\u2019s disease progression","volume":"24","author":"Harrison","year":"2009","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212860_ref34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: what\u2019s the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-212860_ref35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.287.4.455","article-title":"Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group","volume":"287","author":"Hobson","year":"2002","journal-title":"JAMA"},{"key":"10.3233\/JPD-212860_ref36","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1212\/01.wnl.0000183359.50822.f2","article-title":"Progression of motor impairment and disability in Parkinson disease: a population-based study","volume":"65","author":"Alves","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JPD-212860_ref37","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S1353-8020(09)70792-8","article-title":"Sleepiness in Parkinson\u2019s disease","volume":"15 Suppl 3","author":"Arnulf","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212860_ref39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.parkreldis.2018.03.027","article-title":"Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients","volume":"52","author":"Skorvanek","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212860_ref40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2018.01.004","article-title":"Patient-reported outcome measures in the Food and Drug Administration pilot compendium: meeting today\u2019s standards for patient engagement in development?","volume":"21","author":"Oehrlein","year":"2018","journal-title":"Value Health"},{"key":"10.3233\/JPD-212860_ref41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson\u2019s disease severity levels and MDS-Unified Parkinson\u2019s Disease Rating Scale","volume":"21","author":"Mart\u00ednez-Mart\u00edn","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-212860_ref42","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease","volume":"66","author":"P\u00e5lhagen","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JPD-212860_ref43","first-page":"19","article-title":"Correlation between tremor parameters","volume":"17","author":"Milanov","year":"2002","journal-title":"Funct Neurol"},{"key":"10.3233\/JPD-212860_ref44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2125.2012.04192.x","article-title":"Progression of motor and nonmotor features of Parkinson\u2019s disease and their response to treatment","volume":"74","author":"Vu","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JPD-212860_ref45","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/mds.28110","article-title":"Item response theory analysis of the MDS-UPDRS motor examination: tremor vs. nontremor items","volume":"35","author":"Tosin","year":"2020","journal-title":"Mov Disord"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-212860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:50:55Z","timestamp":1777611055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-212860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":43,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jpd-212860","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}